HALOZYME THERAPEUTICS INC (HALO)
Sector: Health Care
2026 Annual Meeting Analysis
HALOZYME THERAPEUTICS INC · Meeting: May 5, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Ms. Connaughton has served since 2018, all attendance requirements are met, she holds two public board seats (well within the four-seat limit), and HALO's 3-year price return of +78.2% outperforms the XBI benchmark by +17.9 percentage points, which is far below the 65-point threshold required to trigger a vote against under the strong-positive TSR tier.
Mr. Posard has served since 2013, attendance is satisfactory, he holds one outside public board seat (Nautilus Biotechnology), and HALO's 3-year outperformance of +17.9pp versus XBI does not meet the 65pp threshold required to trigger a vote against for a director with a strong-positive absolute TSR record.
Both Class I nominees — Bernadette Connaughton and Matthew L. Posard — pass all policy screens. Neither is overboarded, attendance is confirmed above 75%, neither has familial ties to management, independence designations are appropriate, and HALO's strong 3-year total return (+78.2%) relative to the XBI biotech benchmark (+60.3%) shows a +17.9pp outperformance gap that is well below the 65pp threshold needed to trigger a vote against under the strong-positive TSR tier. Both nominees receive a FOR vote.
Say on Pay
✓ FORCEO
Helen I. Torley
Total Comp
$23,166,223
Prior Support
96.1%%
CEO Helen Torley's reported total compensation of $23.2 million for 2025 is significantly above typical benchmarks for a biotechnology CEO, but approximately $10 million of that figure represents a single large one-time performance award granted in December 2025 that only pays out if the company's stock price reaches between $115 and $170 per share — an 86% to 175% increase from the grant-date price — and cannot be earned at all without sustained, ambitious stock price growth over four years; stripping that award out leaves the regular annual compensation package (approximately $13 million) more in line with senior biotech CEO peers. The pay-for-performance alignment check is satisfied: HALO's stock rose 40% during 2025 and 78% over three years, outpacing the XBI biotech benchmark by nearly 18 percentage points, meaning above-benchmark variable pay is backed by genuine shareholder value creation. Prior-year say-on-pay support was 96.1%, well above the 70% threshold, and the program features meaningful clawback provisions, no single-trigger change-in-control benefits, strong stock ownership requirements, and a majority of total pay in performance-linked equity — all consistent with good compensation governance.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
20 yrs
Audit Fees
$2,228,815
Non-Audit Fees
$0
Ernst & Young has been Halozyme's auditor since June 2006 (approximately 20 years), which is below the 25-year tenure threshold that would trigger concern; all fees billed in fiscal 2025 were pure audit fees with zero non-audit, tax, or other fees, giving a non-audit fee ratio of 0% — well within the 50% limit; and Ernst & Young is a Big 4 firm fully appropriate for a $7.3 billion public company.
Overall Assessment
The 2026 Halozyme annual meeting presents three straightforward proposals: two Class I director nominees who both pass all policy screens given the company's strong outperformance versus the XBI biotech benchmark, Ernst & Young's ratification where all fees are pure audit with zero non-audit spend and tenure remains below the 25-year concern threshold, and a say-on-pay vote where a large one-time CEO performance award inflates the reported figure but is structured with genuinely demanding stock price hurdles that align with shareholder interests and is supported by strong actual shareholder returns. All three proposals receive a FOR vote.